Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $120912.0.

  • China Pharma Holdings' Current Deferred Revenue rose 38520.06% to $120912.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $120912.0, marking a year-over-year increase of 38520.06%. This contributed to the annual value of $162208.0 for FY2024, which is 7922.15% up from last year.
  • China Pharma Holdings' Current Deferred Revenue amounted to $120912.0 in Q3 2025, which was up 38520.06% from $77683.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Current Deferred Revenue high stood at $572013.0 for Q1 2021, and its period low was $24920.0 during Q3 2024.
  • Moreover, its 5-year median value for Current Deferred Revenue was $136099.0 (2022), whereas its average is $198975.9.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 8552.09% in 2024, then skyrocketed by 38520.06% in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' Current Deferred Revenue stood at $210028.0 in 2021, then skyrocketed by 147.73% to $520295.0 in 2022, then crashed by 82.6% to $90507.0 in 2023, then soared by 79.22% to $162208.0 in 2024, then dropped by 25.46% to $120912.0 in 2025.
  • Its last three reported values are $120912.0 in Q3 2025, $77683.0 for Q2 2025, and $114435.0 during Q1 2025.